PREP

Results were announced at the virtual 23^rd International AIDS Conference.

In developing countries with overcrowded hospitals, community pharmacies can relive burden, help patients adhere to their regimen, thus offering a viable alternative to patients who need to maintain their medication and keep stable.

PrEP-AP is intended to lower out-of-pocket costs for both uninsured and insured people who are eligible for PrEP services such as laboratory tests.

When taken daily, PrEP is highly effective for preventing HIV from sex or injection drug use.

New research indicates that even with effective antiretroviral treatment, HIV may still affect the central nervous system.
 

Remdesivir, the investigational drug for the treatment of the coronavirus disease 2019 (COVID-19), will be sold for $390 per vial.

Although researchers know that HIV enters the brain within 8 days of infection, less is known about whether HIV-infected brain cells can release the virus, letting it migrate from the brain back into the body to infect other tissues.  
 

Access and adherence to pre-exposure prophylaxis is vital in eradicating the HIV epidemic in the United States.

Closing these gaps in care could improve access for those worse affected by HIV in developing countries.

HIV drug prices rose 34% between 2012 and 2018 and continue to climb, which experts say is a huge issue.

Uptake of PrEP has been slow, particularly among at-risk individuals between 13-19 years of age ar risk for HIV infection.

Pharmacy Times^® interviewed James Krellenstein, co-Founder, PrEP4All Collaboration and Organizer, The COVID-19 Working Group, to discuss the development of PrEP for the COVID-19 pandemic.